NO326517B1 - Anvendelse av biologisk aktive vitamin D-forbindelser for fremstilling av et medikament for profylakse og terapeutisk behandling av inflammatorisk tarmsykdom hvor behandlingen ikke forer til alvorlig hyperkalsemi - Google Patents

Anvendelse av biologisk aktive vitamin D-forbindelser for fremstilling av et medikament for profylakse og terapeutisk behandling av inflammatorisk tarmsykdom hvor behandlingen ikke forer til alvorlig hyperkalsemi Download PDF

Info

Publication number: NO326517B1
Authority: NO; Norway
Prior art keywords: group; biologically active; alkyl; ibd; vitamin
Prior art date: 1999-12-21

Application number

NO20022974A

Other languages

English (en)

Norwegian (no)

Other versions

NO20022974L (no

NO20022974D0 (no

Inventor

Colleen E Hayes

Faye E Nashold

Original Assignee

Wisconsin Alumni Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-21

Filing date

2002-06-20

Publication date

2008-12-22

2002-06-20 Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found

2002-06-20 Publication of NO20022974D0 publication Critical patent/NO20022974D0/no

2002-08-20 Publication of NO20022974L publication Critical patent/NO20022974L/no

2008-12-22 Publication of NO326517B1 publication Critical patent/NO326517B1/no

Links

208000022559 Inflammatory bowel disease Diseases 0.000 title claims description 124
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 title claims description 107
229930003316 Vitamin D Natural products 0.000 title claims description 104
235000019166 vitamin D Nutrition 0.000 title claims description 104
239000011710 vitamin D Substances 0.000 title claims description 104
229940046008 vitamin d Drugs 0.000 title claims description 104
-1 vitamin D compounds Chemical class 0.000 title claims description 93
238000011282 treatment Methods 0.000 title claims description 54
208000037147 Hypercalcaemia Diseases 0.000 title claims description 32
230000000148 hypercalcaemia Effects 0.000 title claims description 32
239000003814 drug Substances 0.000 title claims description 15
229940079593 drug Drugs 0.000 title claims description 11
238000004519 manufacturing process Methods 0.000 title claims description 5
238000011321 prophylaxis Methods 0.000 title claims description 4
230000001225 therapeutic effect Effects 0.000 title description 39
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 74
229960005084 calcitriol Drugs 0.000 claims description 73
208000024891 symptom Diseases 0.000 claims description 50
108090000174 Interleukin-10 Proteins 0.000 claims description 43
102000003814 Interleukin-10 Human genes 0.000 claims description 41
125000000217 alkyl group Chemical group 0.000 claims description 26
229910052739 hydrogen Inorganic materials 0.000 claims description 25
239000001257 hydrogen Substances 0.000 claims description 25
208000030915 hypercalcemia disease Diseases 0.000 claims description 25
150000003710 vitamin D derivatives Chemical class 0.000 claims description 22
125000003709 fluoroalkyl group Chemical group 0.000 claims description 20
150000002431 hydrogen Chemical group 0.000 claims description 20
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 20
125000002252 acyl group Chemical group 0.000 claims description 11
AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 claims description 10
229910052760 oxygen Inorganic materials 0.000 claims description 7
125000004432 carbon atom Chemical group C* 0.000 claims description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 claims description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 5
239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
229910052717 sulfur Inorganic materials 0.000 claims description 5
125000004434 sulfur atom Chemical group 0.000 claims description 5
229940076144 interleukin-10 Drugs 0.000 claims description 4
125000001931 aliphatic group Chemical group 0.000 claims description 3
125000003118 aryl group Chemical group 0.000 claims description 3
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
125000006331 halo benzoyl group Chemical group 0.000 claims description 3
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
241000699670 Mus sp. Species 0.000 description 94
235000020964 calcitriol Nutrition 0.000 description 66
239000011612 calcitriol Substances 0.000 description 66
229960000633 dextran sulfate Drugs 0.000 description 50
238000002360 preparation method Methods 0.000 description 46
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
201000010099 disease Diseases 0.000 description 33
239000011575 calcium Substances 0.000 description 30
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 26
108010054147 Hemoglobins Proteins 0.000 description 26
102000001554 Hemoglobins Human genes 0.000 description 26
229910052791 calcium Inorganic materials 0.000 description 26
210000001072 colon Anatomy 0.000 description 25
230000000694 effects Effects 0.000 description 25
210000003608 fece Anatomy 0.000 description 25
206010009887 colitis Diseases 0.000 description 23
210000004369 blood Anatomy 0.000 description 21
239000008280 blood Substances 0.000 description 21
210000002966 serum Anatomy 0.000 description 21
238000004458 analytical method Methods 0.000 description 20
206010009900 Colitis ulcerative Diseases 0.000 description 19
201000006704 Ulcerative Colitis Diseases 0.000 description 18
230000000968 intestinal effect Effects 0.000 description 18
230000002829 reductive effect Effects 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
150000001875 compounds Chemical class 0.000 description 16
238000000034 method Methods 0.000 description 16
208000011231 Crohn disease Diseases 0.000 description 14
108010063045 Lactoferrin Proteins 0.000 description 14
102000010445 Lactoferrin Human genes 0.000 description 14
239000000872 buffer Substances 0.000 description 14
235000014105 formulated food Nutrition 0.000 description 14
210000001519 tissue Anatomy 0.000 description 14
241001465754 Metazoa Species 0.000 description 13
241000699666 Mus <mouse, genus> Species 0.000 description 13
210000004027 cell Anatomy 0.000 description 13
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 13
229940078795 lactoferrin Drugs 0.000 description 13
235000021242 lactoferrin Nutrition 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 13
239000000523 sample Substances 0.000 description 13
210000001035 gastrointestinal tract Anatomy 0.000 description 12
102000003896 Myeloperoxidases Human genes 0.000 description 11
108090000235 Myeloperoxidases Proteins 0.000 description 11
241000283973 Oryctolagus cuniculus Species 0.000 description 11
208000007502 anemia Diseases 0.000 description 10
235000005911 diet Nutrition 0.000 description 10
208000016261 weight loss Diseases 0.000 description 10
230000004580 weight loss Effects 0.000 description 10
241000282412 Homo Species 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
230000000125 calcaemic effect Effects 0.000 description 9
230000037213 diet Effects 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
206010061218 Inflammation Diseases 0.000 description 8
102100037850 Interferon gamma Human genes 0.000 description 8
108010074328 Interferon-gamma Proteins 0.000 description 8
238000003556 assay Methods 0.000 description 8
230000037396 body weight Effects 0.000 description 8
230000004054 inflammatory process Effects 0.000 description 8
239000000203 mixture Substances 0.000 description 8
239000007787 solid Substances 0.000 description 8
239000000243 solution Substances 0.000 description 8
230000002269 spontaneous effect Effects 0.000 description 8
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
239000002775 capsule Substances 0.000 description 7
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
238000007489 histopathology method Methods 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
230000004044 response Effects 0.000 description 7
208000004998 Abdominal Pain Diseases 0.000 description 6
206010012735 Diarrhoea Diseases 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
206010037660 Pyrexia Diseases 0.000 description 6
206010038063 Rectal haemorrhage Diseases 0.000 description 6
210000000988 bone and bone Anatomy 0.000 description 6
230000001684 chronic effect Effects 0.000 description 6
230000002950 deficient Effects 0.000 description 6
239000000284 extract Substances 0.000 description 6
230000002757 inflammatory effect Effects 0.000 description 6
210000000936 intestine Anatomy 0.000 description 6
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 6
229960005205 prednisolone Drugs 0.000 description 6
230000002265 prevention Effects 0.000 description 6
239000000758 substrate Substances 0.000 description 6
239000003656 tris buffered saline Substances 0.000 description 6
239000011647 vitamin D3 Substances 0.000 description 6
229940021056 vitamin d3 Drugs 0.000 description 6
108090000695 Cytokines Proteins 0.000 description 5
208000005156 Dehydration Diseases 0.000 description 5
206010029148 Nephrolithiasis Diseases 0.000 description 5
241000276498 Pollachius virens Species 0.000 description 5
208000025865 Ulcer Diseases 0.000 description 5
238000002835 absorbance Methods 0.000 description 5
230000009102 absorption Effects 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
230000018678 bone mineralization Effects 0.000 description 5
239000000969 carrier Substances 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000003246 corticosteroid Substances 0.000 description 5
229960001334 corticosteroids Drugs 0.000 description 5
238000002716 delivery method Methods 0.000 description 5
239000003651 drinking water Substances 0.000 description 5
235000020188 drinking water Nutrition 0.000 description 5
230000006870 function Effects 0.000 description 5
230000006698 induction Effects 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
238000010172 mouse model Methods 0.000 description 5
210000000664 rectum Anatomy 0.000 description 5
150000003873 salicylate salts Chemical class 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
102000004127 Cytokines Human genes 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
208000002720 Malnutrition Diseases 0.000 description 4
108091008874 T cell receptors Proteins 0.000 description 4
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
230000000112 colonic effect Effects 0.000 description 4
230000018044 dehydration Effects 0.000 description 4
238000006297 dehydration reaction Methods 0.000 description 4
230000029087 digestion Effects 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
239000003995 emulsifying agent Substances 0.000 description 4
239000002702 enteric coating Substances 0.000 description 4
238000009505 enteric coating Methods 0.000 description 4
239000000945 filler Substances 0.000 description 4
230000028993 immune response Effects 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
239000003018 immunosuppressive agent Substances 0.000 description 4
230000008595 infiltration Effects 0.000 description 4
238000001764 infiltration Methods 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000001071 malnutrition Effects 0.000 description 4
235000000824 malnutrition Nutrition 0.000 description 4
239000000463 material Substances 0.000 description 4
208000015380 nutritional deficiency disease Diseases 0.000 description 4
239000006187 pill Substances 0.000 description 4
230000009467 reduction Effects 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
210000002784 stomach Anatomy 0.000 description 4
239000000829 suppository Substances 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
230000037317 transdermal delivery Effects 0.000 description 4
108050000156 vitamin D receptors Proteins 0.000 description 4
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
208000037157 Azotemia Diseases 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
206010010071 Coma Diseases 0.000 description 3
206010010774 Constipation Diseases 0.000 description 3
206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
208000001953 Hypotension Diseases 0.000 description 3
102000000588 Interleukin-2 Human genes 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
206010024264 Lethargy Diseases 0.000 description 3
208000010428 Muscle Weakness Diseases 0.000 description 3
206010028372 Muscular weakness Diseases 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
206010047700 Vomiting Diseases 0.000 description 3
238000010171 animal model Methods 0.000 description 3
208000022531 anorexia Diseases 0.000 description 3
230000006793 arrhythmia Effects 0.000 description 3
206010003119 arrhythmia Diseases 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
206010061428 decreased appetite Diseases 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000002550 fecal effect Effects 0.000 description 3
108010036302 hemoglobin AS Proteins 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
230000036543 hypotension Effects 0.000 description 3
229940125721 immunosuppressive agent Drugs 0.000 description 3
238000011835 investigation Methods 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
238000011813 knockout mouse model Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
239000012139 lysis buffer Substances 0.000 description 3
201000000173 nephrocalcinosis Diseases 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
230000036269 ulceration Effects 0.000 description 3
102000009310 vitamin D receptors Human genes 0.000 description 3
235000005282 vitamin D3 Nutrition 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 2
206010000060 Abdominal distension Diseases 0.000 description 2
229920002126 Acrylic acid copolymer Polymers 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
101100347633 Drosophila melanogaster Mhc gene Proteins 0.000 description 2
241000792859 Enema Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000283086 Equidae Species 0.000 description 2
208000009386 Experimental Arthritis Diseases 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
206010053759 Growth retardation Diseases 0.000 description 2
101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
208000000913 Kidney Calculi Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000016604 Lyme disease Diseases 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 2
206010028116 Mucosal inflammation Diseases 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
229920002367 Polyisobutene Polymers 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
206010036774 Proctitis Diseases 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
210000000447 Th1 cell Anatomy 0.000 description 2
206010047626 Vitamin D Deficiency Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000004596 appetite loss Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
238000009534 blood test Methods 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
230000008021 deposition Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000007920 enema Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000029142 excretion Effects 0.000 description 2
230000004761 fibrosis Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000009395 genetic defect Effects 0.000 description 2
231100000001 growth retardation Toxicity 0.000 description 2
102000050459 human LTF Human genes 0.000 description 2
238000005805 hydroxylation reaction Methods 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000011532 immunohistochemical staining Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000003960 inflammatory cascade Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000031891 intestinal absorption Effects 0.000 description 2
210000005027 intestinal barrier Anatomy 0.000 description 2
230000007358 intestinal barrier function Effects 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000002429 large intestine Anatomy 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
208000019017 loss of appetite Diseases 0.000 description 2
235000021266 loss of appetite Nutrition 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
239000001095 magnesium carbonate Substances 0.000 description 2
229910000021 magnesium carbonate Inorganic materials 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000008693 nausea Effects 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
150000007523 nucleic acids Chemical group 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
206010036784 proctocolitis Diseases 0.000 description 2
208000017048 proctosigmoiditis Diseases 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
201000010727 rectal prolapse Diseases 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
229960001860 salicylate Drugs 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000008719 thickening Effects 0.000 description 2
201000002516 toxic megacolon Diseases 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
208000009852 uremia Diseases 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
239000012224 working solution Substances 0.000 description 2
CZBGBNZNGSRTCH-XIJCJBARSA-N (1r)-5-[(2e)-2-[(3as,7as)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3h-inden-4-ylidene]ethyl]-6-methylidenecyclohex-3-ene-1,3-diol Chemical compound C1(/[C@@H]2CC=C([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\CC1C=C(O)C[C@@H](O)C1=C CZBGBNZNGSRTCH-XIJCJBARSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
BPKAHTKRCLCHEA-FOPGHSPUSA-N 19-Nor-1-α,25-dihydroxyvitamin D2 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](C=C[C@H](C)C(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-FOPGHSPUSA-N 0.000 description 1
UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
CPBJMKMKNCRKQB-UHFFFAOYSA-N 3,3-bis(4-hydroxy-3-methylphenyl)-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 CPBJMKMKNCRKQB-UHFFFAOYSA-N 0.000 description 1
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
239000005725 8-Hydroxyquinoline Substances 0.000 description 1
235000010585 Ammi visnaga Nutrition 0.000 description 1
244000153158 Ammi visnaga Species 0.000 description 1
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
238000009010 Bradford assay Methods 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical group [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
241000700198 Cavia Species 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
206010016717 Fistula Diseases 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102000004551 Interleukin-10 Receptors Human genes 0.000 description 1
108010017550 Interleukin-10 Receptors Proteins 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
206010022653 Intestinal haemorrhages Diseases 0.000 description 1
206010022678 Intestinal infections Diseases 0.000 description 1
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
206010028124 Mucosal ulceration Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
206010028289 Muscle atrophy Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
YUGCAAVRZWBXEQ-UHFFFAOYSA-N Precholecalciferol Natural products C=1CCC2(C)C(C(C)CCCC(C)C)CCC2C=1C=CC1=C(C)CCC(O)C1 YUGCAAVRZWBXEQ-UHFFFAOYSA-N 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
102000050760 Vitamin D-binding protein Human genes 0.000 description 1
101710179590 Vitamin D-binding protein Proteins 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000007503 antigenic stimulation Effects 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
229940064856 azulfidine Drugs 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000008512 biological response Effects 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
230000008993 bowel inflammation Effects 0.000 description 1
150000001668 calcitriol derivatives Chemical class 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000009084 cardiovascular function Effects 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
210000004534 cecum Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
210000004953 colonic tissue Anatomy 0.000 description 1
238000002052 colonoscopy Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
238000011437 continuous method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
230000010339 dilation Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
210000004921 distal colon Anatomy 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
229940095399 enema Drugs 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
208000010227 enterocolitis Diseases 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
230000003890 fistula Effects 0.000 description 1
239000000834 fixative Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
210000004394 hip joint Anatomy 0.000 description 1
102000052620 human IL10 Human genes 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
230000000121 hypercalcemic effect Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
210000002490 intestinal epithelial cell Anatomy 0.000 description 1
208000003243 intestinal obstruction Diseases 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
238000011819 knockout animal model Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
229910001425 magnesium ion Inorganic materials 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
229960004963 mesalazine Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004682 mucosal barrier function Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
201000000585 muscular atrophy Diseases 0.000 description 1
230000031990 negative regulation of inflammatory response Effects 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000007658 neurological function Effects 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
229960004110 olsalazine Drugs 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229960003540 oxyquinoline Drugs 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000007971 pharmaceutical suspension Substances 0.000 description 1
238000006303 photolysis reaction Methods 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
230000003234 polygenic effect Effects 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
YUGCAAVRZWBXEQ-WHTXLNIXSA-N previtamin D3 Chemical compound C=1([C@@H]2CC[C@@H]([C@]2(CCC=1)C)[C@H](C)CCCC(C)C)\C=C/C1=C(C)CC[C@H](O)C1 YUGCAAVRZWBXEQ-WHTXLNIXSA-N 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
150000003338 secosteroids Chemical class 0.000 description 1
238000002579 sigmoidoscopy Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
230000002037 soft tissue calcification Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229960001940 sulfasalazine Drugs 0.000 description 1
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000013269 sustained drug release Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000012800 visualization Methods 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

NO20022974A 1999-12-21 2002-06-20 Anvendelse av biologisk aktive vitamin D-forbindelser for fremstilling av et medikament for profylakse og terapeutisk behandling av inflammatorisk tarmsykdom hvor behandlingen ikke forer til alvorlig hyperkalsemi NO326517B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/469,985 US6358939B1 (en)	1999-12-21	1999-12-21	Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
PCT/US2000/034913 WO2001046132A1 (fr)	1999-12-21	2000-12-21	Utilisation de composes de vitamine d biologiquement actifs pour prevenir et traiter la maladie intestinale inflammatoire

Publications (3)

Publication Number	Publication Date
NO20022974D0 NO20022974D0 (no)	2002-06-20
NO20022974L NO20022974L (no)	2002-08-20
NO326517B1 true NO326517B1 (no)	2008-12-22

Family

ID=23865828

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20022974A NO326517B1 (no)	1999-12-21	2002-06-20	Anvendelse av biologisk aktive vitamin D-forbindelser for fremstilling av et medikament for profylakse og terapeutisk behandling av inflammatorisk tarmsykdom hvor behandlingen ikke forer til alvorlig hyperkalsemi

Country Status (9)

Country	Link
US (2)	US6358939B1 (fr)
EP (1)	EP1240136A4 (fr)
JP (1)	JP2004502638A (fr)
KR (1)	KR100660508B1 (fr)
AU (1)	AU781113B2 (fr)
CA (1)	CA2395200A1 (fr)
MX (1)	MXPA02006257A (fr)
NO (1)	NO326517B1 (fr)
WO (1)	WO2001046132A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6087350A (en) *	1997-08-29	2000-07-11	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
EP1233942A2 (fr) *	1999-12-02	2002-08-28	The Penn State Research Foundation	Traitement de maladies enteriques inflammatoires avec des composes de la vitamine d
US6989377B2 (en) *	1999-12-21	2006-01-24	Wisconsin Alumni Research Foundation	Treating vitamin D responsive diseases
AU2002902A (en) *	2000-11-14	2002-05-27	Techlab Inc	Method for differentiating irritable bowel syndrome from inflammatory bowel disease (ibd) and for monitoring persons with ibd using total endogenous lactoferrinas a marker
US7582670B2 (en) *	2001-12-13	2009-09-01	Natrogen Therapeutics, Inc.	Methods of treating an inflammatory-related disease
EP1587906A2 (fr) *	2003-01-10	2005-10-26	Eli Lilly And Company	Traitement de vesicant avec des modulateurs du recepteur de la vitamine d de type phenyle-phenyle
US20070037740A1 (en) *	2003-03-04	2007-02-15	Irit Pinchasi	Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
GB0307865D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Pharmaceutical composition
US20050148557A1 (en) *	2003-07-29	2005-07-07	Jin Tian	Use of Vitamin Ds to treat kidney disease
US20050192255A1 (en) *	2003-07-30	2005-09-01	Jin Tian	Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
US20050209203A1 (en) *	2003-07-30	2005-09-22	Jin Tian	Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease
US20060171983A1 (en) *	2003-07-30	2006-08-03	Jin Tian	Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
US7704980B2 (en) *	2003-10-08	2010-04-27	Wisconsin Alumni Research Foundation	Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
GB0513984D0 (en) *	2005-07-07	2005-08-17	Teva Pharma	Dosage form
EP2129382A4 (fr)	2007-02-21	2011-01-19	Univ Michigan	Compositions et procédés de tranquillisation du muscle cardiaque
CA2681582C (fr) *	2007-03-30	2015-07-14	Amgen Inc.	Procedes de traitement de troubles intestinaux
EP2144872A2 (fr) *	2007-04-18	2010-01-20	Johns Hopkins University	Analogues de calcitriol tres antiproliferateur, a calcemie basse
US8318708B2 (en) *	2007-11-06	2012-11-27	Salk Institute For Biological Studies	Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis
JP2011503104A (ja)	2007-11-09	2011-01-27	カリフォルニアインスティテュートオブテクノロジー	免疫調節化合物ならびに関連組成物および方法
CA2981549A1 (fr) *	2009-01-27	2010-08-05	Berg Llc	Vitamines d3 et analogues de celles-ci pour soulagement des effets secondaires associes a une chimiotherapie
CN106265695B (zh)	2009-08-14	2021-05-07	博格有限责任公司	用于治疗脱发的维生素d3及其类似物
JP5681723B2 (ja)	2009-11-20	2015-03-11	ライジェルファーマシューティカルズ，インコーポレイテッド	２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用
JP6027961B2 (ja)	2010-04-07	2016-11-16	シェン, ユエSHEN, Yue	粘膜へ化合物を送るための媒体、それに関連する組成物、方法、及びシステム
CA2792278C (fr)	2010-04-13	2019-05-14	Rigel Pharmaceuticals, Inc.	Composes 2,4-pyrimidinediamine et leurs promedicaments, et leurs utilisations
US20130064859A1 (en) *	2011-01-28	2013-03-14	Sarkis K. Mazmanian	Combinatorial vitamin d and probiotic therapy for inflammatory bowel disease
US9539281B2 (en)	2011-07-12	2017-01-10	The Brigham And Women's Hospital, Inc.	Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP2723330B1 (fr) *	2011-08-19	2015-07-08	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH	Agent de polythérapie contenant des vasoconstricteurs
CN105473147A (zh)	2013-04-24	2016-04-06	萨克生物研究学院	维生素d受体/smad基因组回路门纤维化反应
CA2911826C (fr)	2013-05-10	2022-08-23	California Institute Of Technology	Prevention et traitement probiotiques du cancer du colon
CN112156097A (zh)	2013-05-29	2021-01-01	博格有限责任公司	使用维生素d预防或减轻化疗诱发的脱发
EP3473299A1 (fr)	2013-06-05	2019-04-24	Salk Institute for Biological Studies	Agonistes du récepteur de la vitamine d pour traiter des maladies impliquant l'activité cxcl12
WO2016065042A1 (fr)	2014-10-22	2016-04-28	Extend Biosciences, Inc.	Conjugués de vitamine d thérapeutiques
US9616109B2 (en)	2014-10-22	2017-04-11	Extend Biosciences, Inc.	Insulin vitamin D conjugates
KR102343093B1 (ko)	2015-02-23	2021-12-24	삼성전자주식회사	식기 세척기 및 그 제어방법
WO2016201342A1 (fr)	2015-06-10	2016-12-15	California Institute Of Technology	Traitement du sepsis, compositions, méthodes et systèmes associés
JP6918365B2 (ja)	2015-08-19	2021-08-11	プレジデントアンドフェローズオブハーバードカレッジ	脂質化ｐｓａ組成物および方法
US11491181B2 (en)	2016-07-15	2022-11-08	President And Fellows Of Harvard College	Glycolipid compositions and methods of use
WO2019023149A1 (fr)	2017-07-24	2019-01-31	Salk Institute For Biological Studies	Utilisation d'antagonistes de la protéine 9 contenant un bromodomaine en association avec des agonistes du récepteur de la vitamine d dans le traitement du diabète
KR20250075704A (ko)	2022-09-30	2025-05-28	익스텐드 바이오사이언시즈, 인크.	장기-지속형 부갑상선 호르몬

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4312806A (en)	1981-03-02	1982-01-26	G. D. Searle & Co.	Method and compounds for treating inflammatory bowel disease
US4638043A (en)	1984-11-13	1987-01-20	Thermedics, Inc.	Drug release system
US5310732A (en)	1986-02-03	1994-05-10	The Scripps Research Institute	2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5518725A (en)	1989-09-25	1996-05-21	University Of Utah Research Foundation	Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5824313A (en)	1989-09-25	1998-10-20	University Of Utah Research Foundation	Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5643602A (en)	1989-11-22	1997-07-01	Astra Aktiebolag	Oral composition for the treatment of inflammatory bowel disease
US5216002A (en)	1989-12-21	1993-06-01	Eli Lilly And Company	Method of treating inflammatory bowel disease
JP2811353B2 (ja)	1990-07-06	1998-10-15	ゼリア新薬工業株式会社	炎症性腸疾患予防・治療剤
ZA916555B (en)	1990-08-27	1993-04-28	Lilly Co Eli	Method of treating inflammatory bowel disease
US5391555A (en)	1991-11-12	1995-02-21	Miles Inc.	Methods for treating inflammatory bowel disease with leukotriene synthesis inhibitors
DE4141746A1 (de)	1991-12-13	1993-06-17	Schering Ag	20-methyl-substituierte vitamin d-derivate
US5932214A (en)	1994-08-11	1999-08-03	Biogen, Inc.	Treatment for inflammatory bowel disease with VLA-4 blockers
DK64592D0 (da)	1992-05-14	1992-05-14	Carlbiotech Ltd As	Peptider til terapeutisk behandling
DE4221961A1 (de) *	1992-06-30	1994-01-05	Schering Ag	22-En-25-oxa-Derivate in der Vitamin D-Reihe, Verfahren zu ihrer Herstellung, diese Derivate enthaltenen pharmazeutische Präparate sowie deren Verwendung als Arzneimittel
US5294630A (en)	1992-07-07	1994-03-15	Eli Lilly And Company	Treatment of inflammatory bowel disease
US5368854A (en)	1992-08-20	1994-11-29	Schering Corporation	Use of IL-10 to treat inflammatory bowel disease
IL107185A (en) *	1992-10-06	1998-02-22	Schering Ag	Vitamin d, 25-carboxylic acid derivatives and pharmaceutical compositions containing the same
GB9223061D0 (en)	1992-11-04	1992-12-16	Leo Pharm Prod Ltd	Chemical compounds
HU223042B1 (hu)	1993-04-20	2004-03-01	Hexal Ag.	Parkinson-kór kezelésére alkalmas hatóanyagot tartalmazó tapasz
GB9309422D0 (en)	1993-05-07	1993-06-23	Res Inst Medicine Chem	Chemical compounds
GB9314400D0 (en)	1993-07-12	1993-08-25	Leo Pharm Prod Ltd	Produktionsaktieselskab) chemical compounds
GB9315253D0 (en)	1993-07-23	1993-09-08	Res Inst Medicine Chem	Chemical compounds
US5420109A (en)	1993-11-12	1995-05-30	Houghten Pharmaceuticals, Inc.	Cytokine restraining agents
GB9325415D0 (en)	1993-12-13	1994-02-16	Res Inst Medicine Chem	Chemical compounds
DE4405545A1 (de) *	1994-02-22	1995-08-31	Dietl Hans	Fettlösliche Vitamine enthaltende Zubereitung zur oralen Applikation
GB9405715D0 (en)	1994-03-23	1994-05-11	Res Inst Medicine Chem	Chemical compounds
GB2292079B (en)	1994-08-12	1998-07-15	Flexpharm Ltd	Coated prednisolone preparation for the treatment of inflamatory bowel disease
DK0717034T3 (da)	1994-12-14	1999-10-18	Duphar Int Res	Vitamin D-forbindelser og fremgangsmåde til fremstilling af disse forbindelser
ATE210642T1 (de)	1995-01-23	2001-12-15	Chugai Pharmaceutical Co Ltd	2-substituierte vitamin-d3-derivate
US5877168A (en)	1995-02-10	1999-03-02	Chugai Seiyaku Kabushiki Kaisha	Vitamin D derivative with substituent at the 2β-position
US5569680A (en)	1995-02-13	1996-10-29	Trustees Of The Univ. Of Penna	Method of treating inflammatory bowel disease with tributyrin
US5981597A (en) *	1995-02-13	1999-11-09	Trustees Of The University Of Pennsylvania	Differentiating agents for the treatment of inflammatory intestinal diseases
GB9509764D0 (en)	1995-05-15	1995-07-05	Tillotts Pharma Ag	Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
US5711964A (en)	1995-06-07	1998-01-27	United States Of America	Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US5851548A (en)	1995-06-07	1998-12-22	Gen-Probe Incorporated	Liposomes containing cationic lipids and vitamin D
CN1188189C (zh)	1995-06-07	2005-02-09	奥瑟－麦内尔制药公司	基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途
US5952317A (en)	1995-09-21	1999-09-14	Wisconsin Alumni Research Foundation	Calcitriol derivatives and their uses
DE69606680T2 (de)	1995-10-30	2000-08-17	F. Hoffmann-La Roche Ag, Basel	1-Alpha, 26-dihydroxy-D-homo-vitamin D3
US5889028A (en)	1996-02-09	1999-03-30	Mayo Foundation For Medical Education And Research	Colonic delivery of nicotine to treat inflammatory bowel disease
US5716946A (en)	1996-02-13	1998-02-10	Wisconsin Alumni Research Foundation	Multiple sclerosis treatment
AU710931B2 (en)	1996-02-28	1999-09-30	Sumitomo Pharmaceuticals Company, Limited	Crystalline vitamin D derivative
GB9607034D0 (en)	1996-04-03	1996-06-05	Leo Pharm Prod Ltd	Chemical compounds
PT892638E (pt)	1996-04-04	2003-03-31	Cilag Ag	Formulacao topica de vitamina d a base de lipossomas
US5891865A (en)	1996-10-04	1999-04-06	Wisconsin Alumni Research Foundation	Treatment of arthritic disease induced by infectious agents
AU743514B2 (en) *	1997-05-16	2002-01-24	Women & Infants Hospital	Cyclic ether vitamin D3 compounds, 1alpha (OH) 3-EPI-vitamin D3 compounds and uses thereof
ATE322477T1 (de) *	1997-05-16	2006-04-15	Woman & Infants Hospital	3-epi-vitamin d2 verbindungen und ihre anwendungen
NL1006072C2 (nl)	1997-05-16	1998-11-17	Jacobs Johannes J	Vergister voor het onder aërobe omstandigheden vergisten van dierlijke mest, inrichting en werkwijze voor het onder aërobe omstandigheden vergisten van dierlijke mest onder toepassing van een dergelijke vergister.
US5936105A (en)	1997-06-13	1999-08-10	Tetrionics, Inc.	14-EPI-19-nor-vitamin D compounds and methods
EP0927721A1 (fr) *	1997-12-17	1999-07-07	Schering Aktiengesellschaft	Nouveaux dérivés de la vitamine D ayant des atomes de phosphore sur les chaines latérales, intermédiaires pour leur préparation et leur utilisation pour la préparation de médicaments
US6214373B1 (en) *	1999-10-07	2001-04-10	Snowden-Sutton Associates, Inc.	Nutritional composition for treating inflammatory bowel diseases
EP1233942A2 (fr) *	1999-12-02	2002-08-28	The Penn State Research Foundation	Traitement de maladies enteriques inflammatoires avec des composes de la vitamine d
US20030188756A1 (en) *	2002-08-19	2003-10-09	Cantorna Margherita T	Treatment of inflammatory bowel disease with vitamin d compounds
WO2002020021A1 (fr) *	2000-09-08	2002-03-14	Wisconsin Alumni Research Foundation	1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol et ses applications therapeutiques

1999
- 1999-12-21 US US09/469,985 patent/US6358939B1/en not_active Expired - Fee Related
2000
- 2000-12-21 MX MXPA02006257A patent/MXPA02006257A/es active IP Right Grant
- 2000-12-21 EP EP00986687A patent/EP1240136A4/fr not_active Ceased
- 2000-12-21 KR KR1020027008018A patent/KR100660508B1/ko not_active Expired - Fee Related
- 2000-12-21 WO PCT/US2000/034913 patent/WO2001046132A1/fr not_active Ceased
- 2000-12-21 JP JP2001547043A patent/JP2004502638A/ja not_active Withdrawn
- 2000-12-21 CA CA002395200A patent/CA2395200A1/fr not_active Abandoned
- 2000-12-21 AU AU22878/01A patent/AU781113B2/en not_active Ceased
2001
- 2001-12-21 US US10/036,819 patent/US6858595B2/en not_active Expired - Fee Related
2002
- 2002-06-20 NO NO20022974A patent/NO326517B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU2287801A (en)	2001-07-03
WO2001046132A1 (fr)	2001-06-28
AU781113B2 (en)	2005-05-05
EP1240136A1 (fr)	2002-09-18
KR20020084075A (ko)	2002-11-04
EP1240136A4 (fr)	2004-05-26
CA2395200A1 (fr)	2001-06-28
NO20022974L (no)	2002-08-20
NO20022974D0 (no)	2002-06-20
US20020128241A1 (en)	2002-09-12
KR100660508B1 (ko)	2006-12-22
US6858595B2 (en)	2005-02-22
JP2004502638A (ja)	2004-01-29
US6358939B1 (en)	2002-03-19
MXPA02006257A (es)	2004-12-06

Legal Events

Date	Code	Title	Description
2010-07-19	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO326517B1 (no)	2008-12-22	Anvendelse av biologisk aktive vitamin D-forbindelser for fremstilling av et medikament for profylakse og terapeutisk behandling av inflammatorisk tarmsykdom hvor behandlingen ikke forer til alvorlig hyperkalsemi
US6989377B2 (en)	2006-01-24	Treating vitamin D responsive diseases
Yamamoto et al.	2019	Immunological effects of vitamin D and their relations to autoimmunity
Lara-Villoslada et al.	2006	Oligosaccharides isolated from goat milk reduce intestinal inflammation in a rat model of dextran sodium sulfate-induced colitis
Rudnicki et al.	1997	Effect of 1, 25-dihydroxycholecalciferol on glucose metabolism in gestational diabetes mellitus
Macfarlane et al.	2009	Intestinal bacteria and inflammatory bowel disease
Blair et al.	2008	Prevalence of vitamin D [25 (OH) D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients
JP2018532779A (ja)	2018-11-08	糖尿病及び腸疾患の治療又は予防における使用のためのフィーカリバクテリウムプラウスニッツィ及びデスルホビブリオピゲル
Le Bourgot et al.	2019	Perinatal short-chain fructooligosaccharides program intestinal microbiota and improve enteroinsular axis function and inflammatory status in high-fat diet-fed adult pigs
Huang et al.	2015	A soybean and fish oil mixture with different n-6/n-3 PUFA ratios modulates the inflammatory reaction in mice with dextran sulfate sodium-induced acute colitis
Gou et al.	2018	Effects of oxidative stress induced by high dosage of dietary iron ingested on intestinal damage and caecal microbiota in Chinese Yellow broilers
Ramos et al.	2015	The impact of vitamin D on the innate immune response to uropathogenic Escherichia coli during pregnancy
Geier et al.	2007	Prebiotic and synbiotic fructooligosaccharide administration fails to reduce the severity of experimental colitis in rats
Alake et al.	2023	Wheat germ supplementation reduces inflammation and gut epithelial barrier dysfunction in female interleukin-10 knockout mice fed a pro-atherogenic diet
JP7184805B2 (ja)	2022-12-06	肥満症の予防のためのベタイン
EP1392323A2 (fr)	2004-03-03	Utilisation d'analogue de la vitamine d3 pour le traitement de diabetes auto-immuns
Favus et al.	2018	Idiopathic hypercalciuria and nephrolithiasis
Aburahma et al.	2023	Correlation of Serum Vitamin C Level and Serum Uric Acid with Vitamin D Level in a Sample of Iraqi Rheumatoid Arthritis Patients
Morgan et al.	1995	Diet, body mass index, and colonic epithelial cell proliferation in a healthy population
Hu et al.	2024	Oligosaccharide to short-chain fatty acid mediates food intake and fat synthesis in obese mice
Gillies	2017	Role of calcitriol in regulating maternal bone and mineral metabolism during pregnancy, lactation, and post-weaning recovery
Negrini	2025	Comparison of different zinc sources at EU authorized level for sustaining gut health in weaned pigs in different physiological conditions
Das	1983	Pharmacotherapy of inflammatory bowel disease
Desalermos et al.	2016	Vitamin D and Inflammatory Bowel Disease
NZ566029A (en)	2011-12-22	Vitamin D derivatives for the treatment of type I diabetes